Skip to main content

Advertisement

Log in

Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

CYFRA 21-1 and CEA have been applied for the differential diagnosis of malignant pleural mesothelioma (MPM). The soluble mesothelin-related peptide (SMRP) has been proposed as a specific marker for distinguishing MPM from benign diseases and other malignancies in pleural effusions (PEs). In this study, we evaluated the usefulness of SMRP in PEs in the detection of mesotheliomas by comparing it with that of CYFRA 21-1, CEA, and with cytological examination. One hundred and seventy-seven consecutive patients (57 MPM, 64 metastatic tumors, and 56 benign diseases) were evaluated using commercial tests. The performance of the markers was analyzed by standard ROC analysis methods, using the area under a ROC curve (AUC) as a measure of accuracy. CYFRA 21-1 better differentiated malignant from benign effusions. The corresponding area under the receiver operating characteristic curve was 0.87, while it was 0.74 for SMRP and 0.64 for CEA (p < 0.001). Conversely, SMRP differentiated MPM from all other PEs better than both CYFRA 21-1 and CEA (AUC = 0.84, 0.76, and 0.32, respectively, p = 0.003). Low levels of CEA were associated with a MPM diagnosis. The AUC for differentiating MPM from metastases was 0.81 for SMRP, 0.61 for CYFRA 21-1, and 0.20 for CEA (p < 0.001). In cases with negative or suspicious cytology, SMRP and CYFRA 21-1 identified 36/71 and 46/66 malignant PEs (29 and 31 MPM, respectively). Only 1 MPM showed a high CEA concentration. No single marker showed the best performance in any comparison. Results suggest that SMRP could improve CYFRA 21-1 and CEA accuracy in the differential diagnosis of MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.

    Article  PubMed  CAS  Google Scholar 

  2. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9:147–57.

    Article  PubMed  Google Scholar 

  3. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874–9.

    Article  PubMed  CAS  Google Scholar 

  4. Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol. 2008;9:158–70.

    Article  PubMed  Google Scholar 

  5. Aerts JG, Delahaye M, van der Kwast TH, Davidson B, Hoogsteden HC, van Meerbeeck JP. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol. 2006;34:523–7.

    Article  PubMed  CAS  Google Scholar 

  6. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361:1326–30.

    Article  PubMed  CAS  Google Scholar 

  7. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325–33.

    Article  PubMed  Google Scholar 

  8. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer. 2001;31:9–16.

    Article  PubMed  CAS  Google Scholar 

  9. Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement JP, Housset B. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem. 2000;33:405–10.

    Article  PubMed  CAS  Google Scholar 

  10. van den Heuvel MM, Korse CM, Bonfrer JM, Baas P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer. 2008;59:350–4.

    Article  PubMed  Google Scholar 

  11. Korczynski P, Krenke R, Safianowska A, Gorska K, Abou CMB, Maskey-Warzechowska M, Kondracka A, Nasilowski J, Chazan R. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res. 2009;14:128–33.

    Article  PubMed  Google Scholar 

  12. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist. 2005;10:501–7.

    Article  PubMed  CAS  Google Scholar 

  13. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer. 2003;40:289–94.

    Article  PubMed  Google Scholar 

  14. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, Reyre J, Carles P, Serre G. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81:1059–65.

    Article  PubMed  CAS  Google Scholar 

  15. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66–73.

    Article  PubMed  CAS  Google Scholar 

  16. Barak V, Goike H, Panaretakis K, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529–40.

    Article  PubMed  CAS  Google Scholar 

  17. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–42.

    Article  PubMed  CAS  Google Scholar 

  18. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.

    Article  PubMed  CAS  Google Scholar 

  19. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin–related protein: a blood test for mesothelioma. Lung Cancer. 2005;49:109–11.

    Article  Google Scholar 

  20. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541–9.

    Article  PubMed  Google Scholar 

  21. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007;62:569–76.

    Article  PubMed  Google Scholar 

  22. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin–related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85:265–72.

    Article  PubMed  Google Scholar 

  23. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173:1155–60.

    Article  PubMed  CAS  Google Scholar 

  24. Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J. 2013;41:18–24.

    Article  PubMed  CAS  Google Scholar 

  25. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009;180:437–44.

    Article  PubMed  Google Scholar 

  26. Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T’Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat. 2009;8:323–32.

    PubMed  CAS  Google Scholar 

  27. Light RW. Pleural effusions. Med Clin N Am. 2011;95:1055–70.

    Article  PubMed  Google Scholar 

  28. Sahn SA. Getting the most from pleural fluid analysis. Respirology. 2012;17:270–7.

    Article  PubMed  Google Scholar 

  29. Leers MP, Kleinveld HA, Scharnhorst V. Differentiating transudative from exudative pleural effusion: should we measure effusion cholesterol dehydrogenase? Clin Chem Lab Med. 2007;45:1332–8.

    Article  PubMed  CAS  Google Scholar 

  30. Casal RF, Eapen GA, Morice RC, Jimenez CA. Medical thoracoscopy. Curr Opin Pulm Med. 2009;15:313–20.

    Article  PubMed  Google Scholar 

  31. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010;137:1362–8.

    Article  PubMed  Google Scholar 

  32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.

    Article  PubMed  CAS  Google Scholar 

  33. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press; 2003.

    Google Scholar 

  34. Moll R, Franke WW, Schiller DL, Geiger P, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.

    Article  PubMed  CAS  Google Scholar 

  35. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15–3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63.

    Article  PubMed  Google Scholar 

  36. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398–405.

    Article  PubMed  CAS  Google Scholar 

  37. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13:518–27.

    Article  PubMed  Google Scholar 

  38. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63:35–41.

    Article  PubMed  Google Scholar 

  39. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13:5076–81.

    Article  PubMed  CAS  Google Scholar 

  40. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–53.

    Article  PubMed  CAS  Google Scholar 

  41. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011;85:185–92.

    Article  PubMed  CAS  Google Scholar 

  42. Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest. 2013;31:48–55.

    Article  CAS  Google Scholar 

  43. Fujimoto N, Gemba K, Asano M, Wada S, Ono K, Ozaki S, Kishimoto T. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Exp Ther Med. 2010;1:313–7.

    PubMed  Google Scholar 

  44. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2011;16:44–52.

    Article  PubMed  Google Scholar 

  45. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–19.

    Article  PubMed  CAS  Google Scholar 

  46. Ray M, Kindler HL. Malignant pleural mesothelioma an update on biomarkers and treatment. Chest. 2009;136:888–96.

    Article  PubMed  Google Scholar 

  47. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–28.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to M. Paganuzzi for the advice in managing biomarkers.

Conflict of interest

  None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rosa Filiberti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filiberti, R., Parodi, S., Libener, R. et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. Med Oncol 30, 543 (2013). https://doi.org/10.1007/s12032-013-0543-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0543-6

Keywords

Navigation